Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

Conditions

• Rheumatoid Arthritis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.

Key Dates

First listed

Jul 10, 2023

Start date

Jun 29, 2023

Status verified

Jul 2026

Primary completion

Jan 31, 2028

Completion

Jun 30, 2028

Study Design

Enrollment

1,410 participants (estimated)

Arms

• Arm: Adults diagnosed with RA
  Adults diagnosed with RA who are planning to initiate a new bDMARD +/- csDMARD or tsDMARD +/- csDMARD treatment

Primary Outcome Measure

Clinical Response Prediction [ Time Frame: Approximately 3 months ]

Locations (42)

Find similar trials in Phoenix, AZ

Related Studies

• Physica System Total Knee Replacement Registry Study
  Recruiting · Limacorporate S.p.a · Rancho Mirage, California
• Maternal Autoimmune Disease Research Alliance (MADRA) Registry
  Recruiting · Duke University · Durham, North Carolina
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Sacramento, California
• RA-PRO PRAGMATIC TRIAL
  PHASE3 · Recruiting · University of Alabama at Birmingham · Auburn, Alabama